Navigation Links
Marshall Edwards Announces Publication of Pre-Clinical Studies in Pancreatic Cancer
Date:6/27/2011

SAN DIEGO, June 27, 2011 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from pre-clinical studies of Triphendiol, a prodrug of the Company's lead drug candidate NV-143, that demonstrate its anti-proliferative activity in pancreatic cancer as both a monotherapy and as a chemosensitizer. The publication is now available on the Anti-Cancer Drugs website and scheduled to print in the August issue of the journal.

The studies, conducted in collaboration with lead author Ewan Tytler, Ph.D., at the University of Alabama at Birmingham Medical Center and the Yale University School of Medicine, detail the in vitro activity of Triphendiol in pancreatic cancer cells as well as its in vivo activity in animal models of pancreatic cancer. In addition, both studies show that pre-treatment with Triphendiol enhances the cytotoxic effect of gemcitabine, the standard-of-care chemotherapy currently used to treat advanced pancreatic cancer. An abstract of the publication, entitled "Triphendiol (NV-196), Development of a Novel Therapy for Pancreatic Cancer," can be found at www.marshalledwardsinc.com/our-programs/scientific-publications.

In previous laboratory studies, Triphendiol demonstrated anti-cancer activity against a broad range of tumor cell lines, including breast, colorectal and ovarian. Once administered, Triphendiol is converted in vivo into an active metabolite called NV-143. In addition to being more active than Triphendiol as a single agent, NV-143 appears to be superior in its ability to synergize with chemotherapy in pre-clinical studies. Marshall Edwards has completed the required pre-clinical studies of NV-143 necessary to complete an Investigational New Drug application, which it plans to submit to the U.S. Food and Drug Administration next month.

"These studies add to our growing collection of data regarding the activity of our compounds and their potential ability to enhance the effects of current treatments," said Robert D. Mass, MD, Chief Medical Officer of Marshall Edwards. "These data further support the clinical development strategy for our lead candidate NV-143, the primary metabolite of Triphendiol, in combination with standard-of-care chemotherapy, while expanding the potential drug combinations we can consider in our randomized Phase II clinical trials."

About Marshall Edwards

Marshall Edwards, Inc. (Nasdaq: MSHL) is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The Company's lead programs focus on two families of small molecules that result in the inhibition of tumor cell metabolism. The first and most advanced is a NADH oxidase inhibitor program that includes Triphendiol and lead drug candidate NV-143. The second is a mitochondrial inhibitor program that includes NV-128 and its next-generation candidate NV-344. Both programs are expected to advance into the clinic in 2011. For more information, please visit www.marshalledwardsinc.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.


'/>"/>
SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Marshall Edwards Announces Closing of Asset Purchase Agreement With Novogen
2. Marshall Edwards Announces Private Placement
3. Marshall Edwards Announces Publication of Phase II Clinical Trial Results Highlighting Activity of Intravenous Phenoxodiol
4. Marshall Edwards Receives Positive Response From NASDAQ
5. Marshall Edwards to Host Annual Meeting of Stockholders
6. Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing
7. Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
8. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
9. Edwards Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg
10. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
11. Curaxis Pharmaceutical Corporation Announces Key Changes to Its Board of Directors and Management Team in Progression Toward Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... May 4, 2016 ... the  "Global Actinic Keratosis Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... and Competitive Landscape Highlights 2016, provides comprehensive ... Keratosis epidemiology, Actinic Keratosis market valuations and ...
(Date:5/3/2016)... -- Research and Markets has announced the ... Market Outlook 2020" report to their offering. ... technology has improved significantly in past years due to ... coming years. Many cancer drugs have been developed by ... also expected to be developed with its help. They ...
(Date:5/3/2016)... LAKE OSWEGO, Ore. , May 3, 2016 ... and endovascular medical technology, today announced Food and ... a cardiac resynchronization defibrillator that provides heart failure ... (MRI) scans. Iperia devices also have remote monitoring ... (CLS) that adapts the heart rate in response ...
Breaking Medicine Technology:
(Date:5/5/2016)... Dubuque, IA (PRWEB) , ... May 05, 2016 ... ... his insurance agency’s ongoing community enrichment program serving families of greater Dubuque, IA. ... area’s active duty, reserve and honorably discharged veterans. Donations to Veteran’s Freedom Center ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... among Pittsburgh-area schoolchildren has found that more than 40 percent of participating fifth-grade ... MD , Director of Allergy and Asthma Clinical Research in the Division of ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... TIME for ... safety – today announced a new partnership to reach nearly 1 million children with ... in an instant and is the leading cause of accidental death in children one ...
(Date:5/5/2016)... ... May 05, 2016 , ... Sun Health registered nurse Brittany ... successful Care Transitions program at the 9th Annual Orthopedic and Spine ... in the Post-Acute Environment Through Effective Transitions of Care.” , Major changes are ...
(Date:5/5/2016)... ... ... The 2016 Nike Soccer Camp will be directed by the 2015 Big ... they bring their winning Vandals coaching philosophy to young athletes. Programs are offered for ... school players. Session dates are as follows: , Youth Day Camp – July 11th-14th, ...
Breaking Medicine News(10 mins):